Aldara Keratosis Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
3M's Aldara supplemental NDA cleared FDA March 2 for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults